Vysentri (dasatinib capsule) / Handa Pharma - LARVOL DELTA

[Announcement] Handa Oncology, LLC, a subsidiary of Handa Oncology, LLC505(b)(2) new drug, VYSENTRI (HND-033) US patent lawsuit reached a settlement (litigation ended) [Google translation] (stock.yahoo) - "Reached settlement on behalf of subsidiary Handa Oncology, LLC505(b)(2) new drug, VYSENTRI (HND-033) US patent litigation (finalization of litigation)...BMS will be held at the United States District Court for the Northern on November 8, 2022, US timel; The District of California filed a lawsuit against Handa Oncology, LLC, a US subsidiary of Handa, alleging that it 505(b)(2) VYSENTRI (HND-033 dasatinib) capsules, an improved new drug product, violated its coverage of Sprycel (dasatinib) tablet patent....Handa Oncology, LLC completed the settlement agreement with BMS on June 16, 2023, US time. BMS will honor the settlement agreement agreed terms and conditions, and to withdraw all currently pending lawsuits against Handa Oncology, LLC pursuant to the Settlement Agreement..."

Corporate lawsuit • Patent • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology